Liquidity and Capital Resources (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2016
Cash and cash equivalents	$ 36,426,292	$ 37,643,404	$ 54,972,846	$ 56,959,485
Projected expenditures for preclinical programs	21,100,000
Centurion BioPharma Corporation [Member]
Projected expenditures for preclinical programs	2,300,000
Contract Liabilities [Member]
Projected expenditures for preclinical programs	1,000,000
Other General and Administrative Expenses [Member]
Projected expenditures for preclinical programs	8,000,000
Interest and Principal Payments [Member]
Projected expenditures for preclinical programs	$ 9,800,000